Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AstraZeneca plc (AZN) vs Bank of Montreal (BMO) Price & Performance

AstraZeneca plcTrade
Bank of MontrealTrade

Price performance (Past 24H)

Key statistics

AstraZeneca plc vs Bank of Montreal — how do they compare? AstraZeneca plc trades at $158.25 (market cap $250.84B), while Bank of Montreal trades at $182.04 (market cap $127.25B). The key difference: AstraZeneca plc is the larger of the two by market cap, and Bank of Montreal pays the higher dividend (2.68%). Which is the better fit depends on your goals.

AZNBMO
Market Cap
$250.84B$127.25B
Sector
HealthFinancials
52-Week High
$209.48$183.65
52-Week Low
$147.06$112.54
Enterprise Value
$278.12B
Dividend Yield
1.97%2.68%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AstraZeneca plc

AstraZeneca (AZN) trades at $161.42, up 0.22% today, amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth to $58.74B in 2025 and net income of $10.23B, supported by a P/E of 24.16 and robust profitability margins. Recent news highlights potential talks with Bristol Myers Squibb, though a senior source denied ongoing discussions (Reuters, 2026-08-05).

The outlook is mixed: solid earnings beats and a 47.5% analyst buy rating support upside, but technical weakness and merger uncertainty pose near-term risks. Long-term growth hinges on execution amid competitive and regulatory pressures, with the stock offering value if merger rumors subside and fundamentals prevail.

Bank of Montreal

BMO trades at $181.55, up 0.4% with a bullish technical signal. The company has consistently beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $2.66. Recent strategic moves include the $1.44 billion sale of Moneris and the acquisition of Euroz Hartleys' Australian capital markets business, strengthening its global metals and mining franchise. The stock shows strong fundamental performance with 25.92% net income margin and 11.05% ROE.

BMO presents a balanced investment case with solid earnings momentum and strategic expansion, though trading near resistance at $182. Key opportunities include consistent dividend payments and global banking recognition, while risks involve interest rate sensitivity and competitive pressures in the North American banking sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AstraZeneca plc

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.

Read more on AZN

About Bank of Montreal

Bank of Montreal is a diversified financial-services provider based in North America, operating four business segments: Canadian personal and commercial banking, U.S. P&C banking, wealth management, and capital markets. The bank's operations are primarily in Canada, with a material portion also in the U.S.

Read more on BMO